Drug Profile
Idarucizumab - Boehringer Ingelheim
Alternative Names: BI-655075; Praxbind; PrizbindLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antidotes; Coagulants; Fab fragments; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Blood coagulation disorders
Most Recent Events
- 12 Apr 2021 No development reported - Phase-III for Blood coagulation disorders (In adolescents, In children, In infants, In neonates) in Sweden, Italy, Czech Republic, Sweden, Lithuania, USA, Spain, Bulgaria, Brazil, France, Finland, Austria, Hungary, Israel, Germany, Greece, Israel, Hungary, Russia, Turkey, Ukraine, Belgium (IV, Infusion)
- 12 Apr 2021 No development reported - Phase-III for Blood coagulation disorders (In adolescents, In children, In infants, In neonates) in Sweden, Italy, Czech Republic, Sweden, Lithuania, USA, Spain, Bulgaria, Brazil, France, Finland, Austria, Hungary, Israel, Germany, Greece, Israel, Hungary, Russia, Turkey, Ukraine, Belgium (IV, Injection)
- 02 Jul 2020 Boehringer Ingelheim completes a phase III trial in Coagulation disorders in China (IV) (NCT03343704)